Translational Science and Therapeutics Division

Accelerating Clinical Advances in Cellular and Gene Therapies

The Translational Science and Therapeutics (TST) Division at Fred Hutchinson Cancer Center is composed primarily of laboratory-based research groups that work in areas related to hematopoiesis, immunology, hematopoietic cell transplantation, immunotherapy and gene therapy. The overall goal is to advance our understanding in these research areas and to develop next generation therapies for patients with hematologic malignancies and disorders, solid tumors and infectious diseases.

Dr. Geoff hill writes on a whiteboard

Advancing Research

Our faculty includes 49 researchers focused on developing treatment options, improving patient outcomes and identifying ways to prevent complications from treatments.

Dr. Stan Riddell looks through a microscoope

Developing Therapies

Our investigators are addressing less toxic techniques for eliminating diseased cancer cells and improving the chance of matching blood products for transplantation.

Latest TST News

All TST News
New initiative bolsters Washington state life sciences Fred Hutch researchers awarded over $4M in grants from the Washington Research Foundation November 13, 2024
‘Black hole’ formed by aging cells hobbles key immune organ’s function, regeneration Collaborative project reveals non-functional cells that accumulate in aging thymus August 7, 2024
$5.25M from the Kuni Foundation propels innovative adult oncology research Grants will support research on tumor regression, immunotherapy access and better care for breast, liver and peritoneal malignancies June 28, 2024
Secret to tamping down GVHD may lie in microbial genetics Preclinical bone marrow transplant study shows donor immune cells that target recipient microbiome can influence GVHD severity June 13, 2024